Edwards Lifesciences Corporation’s Stock Price Drops to $68.75, a Decline of 3.01%

Edwards Lifesciences Corporation (EW)

68.75 USD -2.13 (-3.01%) Volume: 5.22M

Edwards Lifesciences Corporation’s stock price is currently at 68.75 USD, experiencing a decline of 3.01% this trading session with a trading volume of 5.22M, reflecting a year-to-date (YTD) percentage change of -9.84%, indicating a challenging market performance for EW.

Latest developments on Edwards Lifesciences Corporation

Today, Edwards Lifesciences Co. (NYSE:EW) experienced fluctuations in its stock price due to various events. Calamos Advisors LLC decreased its stock position in the company, while Baillie Gifford & Co. and New York State Teachers Retirement System both sold shares of Edwards Lifesciences Co. Additionally, the growth of the Intracardiac Oximeter Market, with key players including Edwards Lifesciences Corporation and Medtronic, may have also impacted the stock price movements. Investors are closely monitoring these developments to assess the company’s future performance.

A look at Edwards Lifesciences Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Edwards Lifesciences has a mixed outlook for the future. While the company scores well in areas such as value, growth, and resilience, it falls short in terms of dividend and momentum. This suggests that Edwards Lifesciences may be a solid long-term investment option for those looking for growth and stability, but may not be as attractive for investors seeking regular dividend payouts or companies with strong momentum.

As a company that focuses on treating late-stage cardiovascular disease, Edwards Lifesciences Corporation designs, develops, and markets a range of products and services worldwide. With a balanced overall outlook according to the Smartkarma Smart Scores, Edwards Lifesciences is positioned to continue providing innovative solutions in the healthcare industry, particularly in the field of cardiovascular care.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma